Compare INFU & AVXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INFU | AVXL |
|---|---|---|
| Founded | 2005 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 270.1M | 237.2M |
| IPO Year | 2005 | 2013 |
| Metric | INFU | AVXL |
|---|---|---|
| Price | $13.64 | $1.51 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $16.83 | N/A |
| AVG Volume (30 Days) | 124.0K | ★ 1.1M |
| Earning Date | 11-03-2026 | 11-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 181.82 | N/A |
| EPS | ★ 0.20 | N/A |
| Revenue | ★ $143,436,000.00 | N/A |
| Revenue This Year | $1.20 | N/A |
| Revenue Next Year | $6.16 | N/A |
| P/E Ratio | $68.00 | ★ N/A |
| Revenue Growth | ★ 6.36 | N/A |
| 52 Week Low | $7.29 | $1.44 |
| 52 Week High | $13.85 | $9.50 |
| Indicator | INFU | AVXL |
|---|---|---|
| Relative Strength Index (RSI) | 67.91 | 20.06 |
| Support Level | $8.77 | N/A |
| Resistance Level | $13.85 | $2.80 |
| Average True Range (ATR) | 0.40 | 0.13 |
| MACD | 0.01 | -0.03 |
| Stochastic Oscillator | 83.38 | 6.06 |
InfuSystems Holdings Inc is a health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers. The company's services are provided under two-reportable segments: Patient Services and Device Solutions. Maximum revenue is generated from its Patient Services segment, which provides Durable Medical Equipment (DME) and treatment consumables, handles order and delivery logistics, provides 24/7 nursing support relating to the provided equipment, assumes responsibility for third-party payer Durable Medical Equipment billing, and handles biomedical services for the Durable Medical Equipment. The Device Solutions segment includes equipment rental and sales, consumable sales, and biomedical support services.
Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.